IL-2 therapy in type 1 diabetes: “Trials” and tribulations
Authors:
- Jane H. BucknerJBJane H. Buckner
- Carla J. GreenbaumCGCarla J. Greenbaum
- 1 December 2013
- journal article
- review article
- Published by Elsevier in Clinical Immunology
- Vol. 149 (3) , 324-331
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trialThe Lancet, 2011
- Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseasesNature Reviews Immunology, 2010
- Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell FunctionNew England Journal of Medicine, 2009
- The Biology of Interleukin-2Annual Review of Immunology, 2008
- IL-2 receptor alpha deficiency and features of primary biliary cirrhosisJournal of Autoimmunity, 2006
- Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 DiabetesNew England Journal of Medicine, 2005
- Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes MellitusNew England Journal of Medicine, 2002
- Generalized autoimmune disease in interleukin‐2‐deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cellsEuropean Journal of Immunology, 1995
- Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartmentImmunity, 1995
- Deregulated T Cell Activation and Autoimmunity in Mice Lacking Interleukin-2 Receptor βScience, 1995